Reacta's New R&D Head Signals a Major Push in Allergy Diagnostics

DEESIDE, United Kingdom – August 10, 2026 – In a move that signals a significant acceleration in the food allergy diagnostics space, Reacta Healthcare has appointed Iedena Lima, a 20-year pharmaceutical veteran, as its new Head of Research and Development. While leadership changes are routine, this one is different. It represents a calculated play by a rapidly growing UK biotech to solidify its unique market position and scale its global impact, moving from a niche supplier to a linchpin in the development of next-generation allergy therapies.

Reacta has quietly built a formidable reputation by producing the world's only pharmaceutical-grade oral food challenge (OFC) products. Lima’s appointment is the strategic catalyst intended to leverage this foundation, expand the company’s product arsenal, and deepen its integration into the global clinical trial ecosystem. This isn't just about a new face on the leadership team; it's about fortifying the engine of a company that is fundamentally changing the standards for how food allergies are diagnosed and treated.

The 'Pharma-Grade' Moat in a High-Stakes Market

The global food allergy diagnostics market, valued at over US$3.3 billion in 2025 and projected to grow at a brisk 10.6% CAGR, is ripe for disruption. For decades, clinicians have relied on skin prick and blood tests, which are notorious for high false-positive rates, leaving patients and families with anxiety and unnecessary dietary restrictions. The definitive diagnostic tool is the OFC, where a patient consumes a suspected allergen under strict medical supervision. Yet, the lack of standardized, reliable, and safe challenge materials has long been a critical bottleneck.

This is where Reacta Healthcare has carved out its advantage. The company operates from a dedicated UK facility licensed for Good Manufacturing Practice (GMP) by the Medicines & Healthcare products Regulatory Agency (MHRA). This isn't the GMP standard for food or even medical devices; it's the rigorous pharmaceutical standard applied to medicines. This distinction is paramount. It guarantees a level of purity, dosage accuracy, and batch-to-batch consistency that is simply unattainable with food-grade ingredients. For pharmaceutical companies and CROs running multi-site, multi-year clinical trials for new allergy therapies, this level of quality isn't a luxury—it's a prerequisite for generating reliable data that can withstand regulatory scrutiny.

As Reacta CEO Paul Abrahams stated, “I am delighted to welcome Iedena to the team. Her appointment supports Reacta’s long-term strategy to strengthen and scale our development function, support international growth, and further position the company at the forefront of food allergy diagnostics and clinical research.” The company recently reinforced this competitive moat by securing an extension to its MHRA license, granting it the authority to perform its own in-house analytical testing. This move provides end-to-end control over the quality chain, a critical capability as it prepares to scale.

A Strategic Hire to Supercharge a Proven Growth Engine

Enter Iedena Lima. Her background reads like a blueprint for the exact expertise Reacta needs to execute its next phase of growth. With over two decades of experience at firms like Wockhardt UK, Hikma Pharmaceuticals, and Advanced Woundcare, Lima has a deep track record in formulation development, global regulatory strategy, and leading R&D teams within highly regulated GMP environments. She hasn't just managed development; she has led global programs that secured product approvals across international markets.

This appointment is not about fixing something broken but about adding high-octane fuel to an already accelerating engine. Reacta’s growth has been remarkable. The company doubled its workforce to 80 employees in the last four years and posted an astounding 117% revenue growth over the past three years, earning it a 12th-place ranking in The Sunday Times 100 Tech list for 2026. This trajectory has been powered by strategic investments, including over £2.8 million from the Development Bank of Wales and a £2.9 million funding round led by Praetura Ventures. This capital wasn't just for keeping the lights on; it was purposefully deployed to secure the coveted MHRA license, scale manufacturing, and bring R&D capabilities in-house—a process Lima is now set to lead.

Expanding the Arsenal Against the 'Top 9' Allergens

With a solid foundation and a seasoned leader at the R&D helm, Reacta is poised to rapidly expand its product portfolio. The company started with peanut challenges but has already launched pharmaceutical-grade milk and egg OFCs, with prototypes for hazelnut and cashew in development. The strategic vision is clear: to develop challenge products for all of the "Top 9" major food allergens, a move that directly addresses the complex reality of patients who often suffer from multiple allergies.

Crucially, Reacta’s patented technology allows it to create placebo products that are indistinguishable in taste, texture, and appearance from the active allergen challenges. This is vital for conducting the most rigorous form of clinical study: the double-blind, placebo-controlled food challenge (DBPCFC), which eliminates bias and provides the highest quality evidence. Lima's expertise in formulation will be instrumental in refining and expanding this technically complex work, especially as the company pushes into pediatric solutions for children as young as six months.

Reflecting on her new role, Iedena Lima commented, “Reacta is already a leader in applying pharmaceutical industry standards to improve the safety, accuracy and efficiency of food allergy testing. I look forward to working with the team to develop our portfolio and serve the growing customer base for our OFC products which play a vital role in the development of therapies and diagnostics to transform the lives of the millions of people living with food allergy worldwide.” Her arrival marks a clear inflection point, signaling Reacta's transition from a promising UK success story to an indispensable partner in the global fight against food allergies.